Ewing Sarcoma is a malignant bone and soft tissue tumor driven by EWSR1 fusion genes, predominantly affecting children and adolescents, with high relapse and metastasis risk. Alfa Cytology is a global leader in cancer research. With our extensive experience and advanced platforms, our talented scientists provide one-stop solutions for Ewing Sarcoma animal model development, efficacy evaluation, bone orthotopic model validation, lung metastasis evaluation, postoperative relapse studies, tumor immunology testing, target expression validation, bone destruction testing, pathology testing, molecular mechanism testing, and PK/PD, based on client candidate drugs, fusion gene background, target expression, bone growth requirement, lung metastasis risk, radiotherapy combination strategy, immune system requirements, and R&D stages. We also provide zebrafish experimental services and cell-based experimental services, covering diverse research needs from in vitro to in vivo and from high-throughput screening to mechanism validation.
Ewing Sarcoma is a malignant bone and soft tissue tumor originating from neuroectodermal or mesenchymal stem cells, predominantly affecting children and adolescents, and is the second most common primary bone malignancy worldwide. Ewing Sarcoma is driven by EWSR1::FLI1 and related EWSR1 fusion genes, and is characterized by strong invasiveness and high relapse and metastasis risk. Clinically, Ewing Sarcoma is commonly treated with a multimodal strategy combining multi-agent chemotherapy, surgery, and radiotherapy. Relapsed/refractory and metastatic Ewing Sarcoma relies more on novel targeted agents, ADCs, TCEs, CAR-T/NK, and immunotherapy. Transcriptional regulation, epigenetic regulation, and DNA damage repair downstream of the EWSR1::FLI1 fusion protein are important directions in current drug development. The most common metastatic organ in Ewing Sarcoma is the lung, while local bone invasion, cortical bone destruction, and postoperative relapse are high-priority scenarios in translational research. Fusion transcripts, CD99, and downstream pathway markers play important roles in mechanism research and efficacy evaluation. The Ewing Sarcoma immune microenvironment is relatively unique, and TCE, CAR-T/NK, and humanized immunotherapy have high research value in this cancer type.
Fig. 1 Schematic of the mechanism of action of novel agents for the treatment of Ewing sarcoma. (Daley JDL, et al.; 2025)
Alfa Cytology has established a comprehensive solution platform for Ewing Sarcoma animal experimental research, built around EWSR1::FLI1 fusion gene-driven disease, bone orthotopic microenvironment, bone destruction, local invasion, lung metastasis, postoperative relapse, minimal residual disease, radiotherapy combination, fusion protein-related targeting, epigenetic regulation, ADC, TCE, CAR-T/NK, and humanized immunotherapy scenarios. Leveraging this integrated platform, Alfa Cytology provides end-to-end services covering the full Ewing Sarcoma research workflow.
Ewing Sarcoma drug development requires model selection based on fusion gene background, target expression, bone growth requirement, lung metastasis risk, radiotherapy combination strategy, immune system requirements, and R&D stages. Alfa Cytology provides integrated animal study solutions, from cell line selection to model validation, for fusion protein-related targeted agents, epigenetic regulators, DNA damage repair agents, cytotoxic agents, ADCs, bispecifics, TCEs, CAR-T/NK, humanized immunotherapy, and radiotherapy combination programs.
Candidate Screening
Early screening typically requires rapid assessment of whether a candidate demonstrates in vivo antitumor signals. Alfa Cytology conducts TGI, RTV, PK/PD, CD99, EWSR1::FLI1 fusion transcript, and target evaluations using subcutaneous CDX models, providing data to support dose selection, dosing frequency, and candidate prioritization.
Clinical Relevance Studies
When programs advance to bone orthotopic microenvironment, bone destruction, local invasion, lung metastasis, postoperative relapse, minimal residual disease, or radiotherapy combination stages, Alfa Cytology can further configure bone orthotopic models, experimental lung metastasis models, bone orthotopic spontaneous lung metastasis models, postoperative relapse models, or humanized immune models to help clients generate evidence more aligned with clinical scenarios.
Ewing Sarcoma Mechanism Research
For Ewing Sarcoma studies, experimental design typically needs to address fusion gene background, bone microenvironment, bone destruction, lung metastasis, immune microenvironment, and resistance mechanisms simultaneously. Alfa Cytology provides model development, dosing intervention, pathology testing, immunology testing, protein testing, and RNA testing services, covering EWSR1::FLI1 fusion transcript, CD99, γH2AX, PARP, cell cycle, epigenetic regulation, radiotherapy response, lung metastasis, and MRD clearance.
In Vitro and In Vivo Layered Validation
Animal studies can address whether a candidate inhibits tumor growth, intraosseous burden, bone destruction, lung metastasis, or postoperative relapse; zebrafish platforms provide high-throughput in vivo screening covering tumor proliferation, intraosseous colonization, bone destruction, lung metastatic invasion, angiogenesis, immune co-culture, and drug toxicity; cell-based experiments validate proliferation, apoptosis, migration and invasion, EWSR1::FLI1 fusion, CD99, DNA damage repair, drug internalization, and immune killing.
Molecular Mechanism Studies
Depending on program needs, we offer IHC, IF, flow cytometry, ELISA, Western blot, qPCR, RNA-seq, CD99, EWSR1::FLI1 fusion transcript, Ki67, cleaved caspase-3, γH2AX, PARP, cell cycle markers, angiogenesis markers, hCD45 reconstitution rate, hCD3, hCD8, hNK, cytokines, tumor tissue drug concentration, and bone tissue exposure testing.
For clients with only a candidate drug, target direction, or preliminary mechanistic hypothesis, Alfa Cytology assists in structuring cell line selection, model pathways, group design, dosing regimens, detection endpoints, terminal sample collection, and data presentation，translating R&D questions into executable animal study protocols. Our capabilities support a broad spectrum of therapeutic modalities, including but not limited to:
| R&D Project | Cell Lines | Host System | Preferred Model | Key Endpoints |
| Early efficacy screening | A673, TC-71, RDES, EW8, SK-ES-1 | BALB/c nude, NOD-SCID, NSG, NOG | Subcutaneous CDX | TGI, RTV, terminal tumor weight, CD99, Ki67, cleaved caspase-3, PK/PD. |
| EWSR1::FLI1 fusion research | A673, TC-71, RDES, EW8 | BALB/c nude, NOD-SCID, NSG, NOG | Fusion-defined CDX, orthotopic validation | EWSR1::FLI1 transcript, CD99, transcriptional markers, TGI, pathway. |
| Epigenetic / transcriptional targeting | A673, TC-71, RDES, EW8, SK-ES-1 | BALB/c nude, NOD-SCID, NSG | Multi-line CDX, orthotopic or relapse validation | Fusion transcript, downstream genes, cell cycle, apoptosis, TGI, survival. |
| Cytotoxic and standard chemotherapy | A673, TC-71, RDES, EW8 | BALB/c nude, NOD-SCID, NSG | Subcutaneous CDX, orthotopic validation | TGI, RTV, necrosis, γH2AX, Ki67, orthotopic burden. |
| Relapsed/refractory / topoisomerase | A673, TC-71, SK-ES-1, RDES | BALB/c nude, NOD-SCID, NSG | Subcutaneous CDX, lung metastasis or relapse validation | TGI, survival, lung nodules, BLI, relapse time, DNA damage markers. |
| ADC, nanomedicine, target expression | A673, TC-71, RDES, EW8, SK-ES-1 | BALB/c nude, NOD-SCID, NSG | Target-positive CDX, orthotopic or lung metastasis validation | Target expression, ADC distribution, TGI, bone exposure, PK/PD. |
| Bone microenvironment and destruction | A673-luc, TC-71-luc, RDES-luc, EW8-luc | NOD-SCID, NSG, NOG | Tibial/femoral orthotopic model | Orthotopic burden, BLI, X-ray, micro-CT, bone destruction score, survival. |
| Local delivery / bone exposure / sustained release | A673-luc, TC-71-luc, RDES-luc | NOD-SCID, NSG, NOG | Orthotopic model | Bone drug concentration, local exposure, bone destruction, local toxicity. |
| Radiotherapy combination / radiosensitization | A673-luc, TC-71-luc, RDES-luc, EW8-luc | NOD-SCID, NSG, NOG | Orthotopic model, with post-resection relapse | Orthotopic burden, residual after RT, γH2AX, necrosis, relapse time. |
| Experimental lung metastasis | A673-luc, TC-71-luc, SK-ES-1-luc, RDES-luc | NOD-SCID, NSG, NOG | Tail vein lung colonization model | Lung BLI, lung nodules, lung weight, pathology, survival. |
| Orthotopic spontaneous lung metastasis | A673-luc, TC-71-luc, RDES-luc, EW8-luc | NOD-SCID, NSG, NOG | Orthotopic long-term follow-up | Orthotopic burden, bone destruction, lung metastasis, survival. |
| Post-surgery recurrence / MRD | A673-luc, TC-71-luc, RDES-luc | NOD-SCID, NSG, NOG | Orthotopic model + amputation/resection follow-up | Recurrence time, local relapse, lung metastasis, BLI, survival. |
| Humanized immunotherapy / CD47 / macrophage | A673, TC-71, RDES, EW8 | CD34+ HSC NSG-SGM3 or NSG/NOG | Humanized orthotopic model | hCD45, hCD3, hCD8, hNK, hCD14/macrophages, cytokines, survival. |
| TCE / CAR-T/NK / human immune-dependent | A673, TC-71, RDES, EW8, SK-ES-1 | huPBMC or huHSC NSG/NOG | Humanized immune model | hCD45, hCD3, hCD8, hNK, T cell activation, cytokines, CRS/xGvHD risk. |
| Multi-line robustness / PDX | A673, TC-71, RDES, EW8, SK-ES-1 or PDX | BALB/c nude, NOD-SCID, NSG | Multi-line CDX or PDX | Multi-model TGI, fusion retention, pathology consistency, PK/PD. |
For Ewing Sarcoma programs focused on EWSR1::FLI1 fusion-driven disease, bone orthotopic microenvironment, bone destruction, and lung metastasis evaluation, we configure TGI, RTV, terminal tumor weight, BLI/IVIS, orthotopic tumor burden, X-ray, micro-CT, bone destruction score, lung nodule count, lung weight, survival, CD99, EWSR1::FLI1 fusion transcript, Ki67, cleaved caspase-3, γH2AX, PARP, cell cycle markers, angiogenesis markers, hCD45 reconstitution rate, hCD3, hCD8, hNK, cytokines, tumor tissue drug concentration, and bone tissue exposure, forming an integrated data chain linking fusion gene background, bone microenvironment, lung metastasis, and immune microenvironment.
Multimodal In Vivo Imaging
Pathology and IHC/IF Staining
TME Microenvironment and Immune Profiling
Alfa Cytology's ewing sarcoma cell line panel covers EWSR1::FLI1 fusion gene-driven disease, bone orthotopic microenvironment, lung metastasis, epigenetic/transcriptional regulation, and immuno-oncology, enabling cell line selection and matching based on fusion gene background, target expression, metastatic potential, and immune system requirements.
EWSR1::FLI1-Representative Cell Lines
Other Commonly Used Ewing Sarcoma Cell Lines
Luc-Labeled and High-Metastasis Derivatives
Fusion Gene and Target Validation Requirements
Alfa Cytology provides end-to-end Ewing Sarcoma animal model development services, spanning model design, cell line selection, model construction, dosing intervention, efficacy evaluation, pathology, immunology, molecular mechanism testing, and PK/PD analysis. The models below represent our core capabilities across EWSR1::FLI1 fusion gene-driven disease, bone orthotopic microenvironment, bone destruction, local invasion, lung metastasis, postoperative relapse, minimal residual disease, radiotherapy combination, fusion protein-related targeting, epigenetic regulation, ADC, TCE, CAR-T/NK, and humanized immunotherapy research. Each model can be customized to match your program's fusion gene background, target expression, bone growth requirement, lung metastasis risk, radiotherapy combination strategy, immune system requirements, and R&D stage, from early screening to clinical relevance validation.
Subcutaneous Xenograft Model (CDX)
Subcutaneous CDX models typically involve inoculating human Ewing Sarcoma cells or tumor fragments subcutaneously into immunodeficient mice, followed by randomization and dosing once tumors reach a predetermined volume. Commonly used hosts include BALB/c nude, NOD-SCID, NSG, and NOG mice. Commonly used cell lines include A673, TC-71, RDES, EW8, and SK-ES-1. Conventional inoculation amounts can reference 1×106–5×106 cells, or 20–40 mm3 tumor fragments, with enrollment volume typically 80–150 mm3.
Model characteristics
A673 subcutaneous CDX is suitable for small molecules, cytotoxic agents, ADCs, nanomedicine, and fusion gene-related targeted strategy early screening. TC-71 subcutaneous CDX is suitable for conventional cytotoxic agents, targeted agents, ADCs, and combination therapy early evaluation. RDES, EW8, and SK-ES-1 can supplement different growth rates, invasion backgrounds, and drug sensitivities. This model has high standardization and good reproducibility, suitable for early screening and PK/PD research; its limitations are the lack of bone microenvironment, bone destruction, bone marrow cavity pressure, lung metastasis cascade, and postoperative relapse processes.
Modeling and dosing timelines
Subcutaneous inoculation typically reaches enrollment volume within 1–3 weeks, with randomization commonly performed at tumor volumes of approximately 80–150 mm3. The conventional treatment period is 2–4 weeks. For resistance, withdrawal rechallenge, long-term exposure, or sustained-release formulations, this can be extended to 4–8 weeks. If the program involves fusion genes, DNA damage, ADCs, or human immune-dependent mechanisms, fusion transcripts, target antigen expression, and mechanism readouts should be re-verified before enrollment or at the endpoint stage.
Detection endpoints
Recommended positive controls
Vincristine at 0.5–1 mg/kg IV or IP, once weekly; doxorubicin at 2–5 mg/kg IV or IP, once weekly or cyclically; cyclophosphamide at 50–100 mg/kg IP. Irinotecan at 10–20 mg/kg IP, for several consecutive days or cyclically; temozolomide at 25–50 mg/kg oral daily for 5 consecutive days. Regorafenib at 10–30 mg/kg oral daily; pazopanib at 30–100 mg/kg oral daily. Lurbinectedin, TK216, and seclidemstat can serve as frontier development references.
Bone Orthotopic Model
Bone orthotopic models typically use A673-luc, TC-71-luc, RDES-luc, or EW8-luc, established via intratibial or intrafemoral injection in NOD-SCID, NSG, or NOG mice, to simulate bone growth, bone destruction, local invasion, and lung metastasis front-end processes.
Model characteristics
A673 bone orthotopic models are suitable for bone growth, bone destruction, local invasion, lung metastasis front-end processes, and postoperative relapse research. TC-71 bone orthotopic models are suitable for orthotopic tumor control, bone destruction, radiotherapy combination, and metastasis research. RDES-luc and EW8-luc bone orthotopic models can supplement different invasiveness and treatment response backgrounds. This model is closer to the real disease scenario of Ewing Sarcoma, suitable for bone destruction, local invasion, radiotherapy combination, and spontaneous lung metastasis research. Its limitations are complex procedures, lower throughput, greater inter-batch variability, and higher requirements for imaging and BLI monitoring.
Modeling and dosing timelines
Bone orthotopic inoculation typically forms monitorable orthotopic burden within several weeks. Dynamic evaluation is recommended with BLI, X-ray, micro-CT, and limb observation. The conventional treatment period is 3–6 weeks. If studying postoperative relapse, lung metastasis, or long-term anti-bone destruction, this can be extended to 6–10 weeks. Enrollment can occur after BLI positivity, X-ray evidence of bone destruction, or orthotopic burden reaching a predetermined standard.
Detection endpoints
Recommended positive controls
VDC/IE-equivalent chemotherapy framework as a basic bone orthotopic model reference. Irinotecan combined with temozolomide for bone orthotopic refractory relapse direction reference. Radiotherapy sensitization programs can set local radiotherapy alone, drug alone, and combination groups. Local formulations or intraosseous sustained-release programs should set blank vehicle, systemic dosing, and local dosing controls.
Experimental Lung Metastasis Model
Experimental lung metastasis models typically involve tail vein injection of A673-luc, TC-71-luc, SK-ES-1-luc, or RDES-luc, focusing on lung colonization after circulation and intrapulmonary expansion.
Model characteristics
Suitable for anti-colonization, anti-metastasis, refractory relapse, systemic therapy, and advanced dissemination latter-half research. This model has relatively shorter cycles and good reproducibility, but mainly reflects the lung colonization stage and does not fully represent the natural process from bone orthotopic lesion to lung metastasis.
Detection endpoints
Lung BLI, lung nodule count, lung weight, lung tissue HE, metastatic area, Ki67, apoptosis, and survival.
Recommended positive controls
VDC/IE-equivalent chemotherapy framework, irinotecan combined with temozolomide, regorafenib, or pazopanib can be set as references based on program positioning. Lurbinectedin, TK216, and seclidemstat can serve as transcriptional regulation, FET fusion, or epigenetic direction development references.
Bone Orthotopic Spontaneous Lung Metastasis Model
Bone orthotopic spontaneous lung metastasis models are typically based on A673-luc or TC-71-luc tibial/femoral orthotopic models, continuously observing lung metastasis formation after primary lesion expansion.
Model characteristics
Suitable for anti-metastasis, distant relapse after local control, perioperative therapy, and long-term maintenance therapy research. This model is closer to the clinical metastasis cascade but has longer cycles and greater variability in metastasis incidence and time window, requiring stable luc labeling and sufficient follow-up time.
Detection endpoints
Orthotopic burden, bone destruction, lung metastasis BLI, lung nodule count, lung tissue pathology, survival, and metastasis-related mechanism markers.
Recommended positive controls
VDC/IE-equivalent chemotherapy framework, irinotecan combined with temozolomide, regorafenib, or pazopanib can be set as references based on program positioning. Lurbinectedin, TK216, and seclidemstat can serve as frontier mechanism development references.
Humanized Immune and Immune-Related Models
Humanized immune models reconstruct the human immune environment by infusing human peripheral blood mononuclear cells or human hematopoietic stem cells into immunodeficient mice, suitable for TCE, CAR-T/NK, human cytokines, human immune checkpoints, bispecifics, and ADCs highly dependent on human immune effects. A673, TC-71, RDES, EW8, or SK-ES-1 can be used for subcutaneous, bone orthotopic, or short-term systemic bridging design. CD34+ HSC-reconstituted NSG-SGM3 or NSG/NOG mice, followed by bone orthotopic Ewing Sarcoma model establishment, can be used for human immune effect research closer to the bone immune microenvironment, suitable for CD47/macrophage remodeling, antibody-based immunotherapy, and complex immune combinations.
Model characteristics
The huPBMC model is suitable for short-cycle human immune effector validation, the huHSC model is suitable for long-cycle human immune reconstitution, complex combination therapy, and immune resistance research, and the CD34+ HSC humanized bone orthotopic model is suitable for programs that need to simultaneously answer whether bone orthotopic efficacy is achieved, whether the human immune system is involved, and whether cytokine risk is controllable. This model has high cost, long cycles, significant donor variability, and carries xGvHD or cytokine release risk; it is not recommended as a first-round high-throughput early screening platform.
Detection endpoints
hCD45, hCD3, hCD4, hCD8, hNK, T cell activation, tumor infiltration, IFN-γ, TNF-α, IL-6, Granzyme B, tumor burden, body weight, CRS, and xGvHD risk markers. huHSC models should also detect human immune reconstitution ratio, T/B/NK/myeloid cell spectrum, hCD14/macrophages, orthotopic burden, and survival.
Recommended positive controls
anti-human PD-1 antibody and anti-human PD-L1 antibody can serve as mechanism references. TCE, CAR-T, or CAR-NK programs should include target-positive, low/negative, effector cell, and empty vector controls. CD47/macrophage remodeling programs can set corresponding human mechanism references.
Radiotherapy Combination, Postoperative Relapse, and MRD Models
Radiotherapy combination models are typically based on A673-luc, TC-71-luc, RDES-luc, or EW8-luc bone orthotopic models, with local radiotherapy performed after orthotopic lesions reach a predetermined burden, followed by candidate drug or combination regimen. Postoperative relapse models typically first establish bone orthotopic lesions, followed by amputation, local resection, or debulking, then tracking local relapse, lung metastasis, and survival. MRD models can be established via low-burden bone orthotopic models, post-local-treatment residual disease, post-induction-therapy residual disease, or postoperative relapse window.
Model characteristics
Radiotherapy combination models are suitable for radiosensitizers, DNA damage agents, local relapse control, bone pain-related programs, and local therapy combination research. Postoperative relapse models are suitable for perioperative therapy, postoperative adjuvant therapy, MRD clearance, anti-relapse, and anti-metastasis strategy research. MRD models are suitable for maintenance therapy, immune clearance, relapse delay, long-term targeted agent dosing, and anti-metastasis strategy research. This model has strong clinical mapping but is technically complex with longer cycles, requiring high consistency in orthotopic modeling, local treatment, and long-term follow-up; it is not suitable for first-round large-scale screening.
Modeling and dosing timelines
Radiotherapy combination programs should clarify irradiation site, dose, fractionation, dosing sequence, and sampling window. Postoperative relapse models first establish bone orthotopic lesions, followed by amputation, local resection, or debulking, then tracking local relapse, lung metastasis, and survival. MRD models can be established via low-burden bone orthotopic, post-local-treatment residual disease, or post-induction-therapy residual disease.
Detection endpoints
Recommended positive controls
Local radiotherapy can be combined with vincristine, doxorubicin, cyclophosphamide, irinotecan/temozolomide, or DNA damage-related candidate drugs. VDC/IE-equivalent chemotherapy framework or irinotecan combined with temozolomide can serve as postoperative adjuvant and refractory relapse references. Regorafenib, pazopanib, lurbinectedin, TK216, or seclidemstat can serve as development references based on program mechanism.
By Development Stage
By Drug Type
By Research Objective
By Route of Administration
By Development Pathway
Oncogenic Fusion-Driven Modeling
Ewing sarcoma is pathognomonic for path-defining pathogenetic fusion oncogenes, most notably EWSR1-FLI1. Alfa Cytology designs tailored evaluation pathways centered on chimeric transcription factor activation, stemness features, and specific downstream transcriptional networks, avoiding generalized sarcoma modeling.
Stratified Cell Line & PDX Directory
Model choice determines sensitivity readouts for DNA damage response inhibitors, targeted radioligands, and cell therapies. Alfa Cytology helps clients match robust systems, such as A673, TC-71, SK-N-MC, RD-ES, and molecularly validated PDX models, based on fusion transcript variant (Type 1 vs. Type 2), p53/STAG2 mutation status, and metastatic potential.
Orthotopic Intra-Osseous & Systemic Metastasis Models
Subcutaneous CDX models miss critical bone-tumor microenvironment crosstalk, bone remodeling dynamics, and multi-organ tropism. Alfa Cytology helps clients generate clinical-correlative evidence through orthotopic intra-osseous (intra-femoral/tibial) and systemic dissemination models.
Target Validation & Integrated PK/PD Workflows
Programs targeting EWSR1-FLI1 downstream targets, PARP, CD99, or IGF-1R require longitudinal biomarker kinetics. Alfa Cytology configures fusion status verification, bone density/lysis tracking, and integrated PK/PD workflows to evaluate deep systemic regression.
Alfa Cytology is a global leader in ewing sarcoma translational research, delivering integrated animal model solutions that span EWSR1::FLI1 fusion-driven disease, bone orthotopic microenvironment, bone destruction, lung metastasis, and immune microenvironment evaluation. If you are interested in our services, please do not hesitate to contact us to learn how we can accelerate your Ewing Sarcoma drug development.
Reference
For research use only.
Alfa Cytology, a preclinical research solution provider, provides its clients with one-stop solutions to accelerate cancer therapeutics discovery and development.
Copyright © 2026 Alfa Cytology. All rights reserved.
